Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2022.08.746 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis.
BMC Cardiovasc Disord
January 2025
The second Affiliated Hospital of Xi'an Jiaotong University, Xinjiang Hospital (People's Hospital of Xinjiang Uygur Autonomous Region, Bainiaohu Hospital), Urumqi, Xinjiang, 830026, People's Republic of China.
Background: Several studies showed higher risks of cardiovascular complications to have been observed in patients with type 2 diabetes mellitus (T2DM). Atrial fibrillation (AF) and atrial flutter have been more pronounced in patients with hyperglycemia. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are now considered as second-line treatment for patients with T2DM following inadequate glycemic control with first line agents.
View Article and Find Full Text PDFAge-dependent effects of SGLT2 inhibitors on stroke risk in geriatric patients with diabetes and atrial fibrillation.
Cardiovasc Diabetol
January 2025
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan, ROC.
Background: Atrial fibrillation (AF) and diabetes mellitus (DM) are associated with an increased risk of ischemic stroke, particularly in geriatric populations. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiovascular benefits, but their effects on stroke risk may vary by age. This study aimed to explore the age-dependent effects of SGLT2i on stroke risk in patients with AF and DM.
View Article and Find Full Text PDFObjective: This study aimed to investigate the association between dapagliflozin and the incidence of atrial fibrillation (AF) and atrial flutter (AFL), along with its impact on all-cause mortality in patients with diabetes mellitus (DM).
Material And Methods: Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, this meta-analysis conducted a comprehensive search across PubMed, Embase, and ClinicalTrials.gov databases up to June 2021.
Effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on the clinical outcomes of patients with diabetic atrial fibrillation.
BMC Cardiovasc Disord
December 2024
Department of Cardiology, Atatürk University Faculty of Medicine, Erzurum, Turkey.
Background: Diabetes mellitus (DM) and atrial Fibrillation (AF) are among the most common health issues. They are responsible for the highest rates of morbidity and mortality. The importance of sodium glucose cotransporter-2 inhibitors (SGLT-2is) in treating DM has increased significantly in recent years.
View Article and Find Full Text PDFDapagliflozin and Sirtuin-1 interaction and mechanism for ameliorating atrial fibrillation in a streptozotocin-induced rodent diabetic model.
Biomol Biomed
January 2025
Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Division of Cardiology, Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Article Synopsis
- Atrial fibrillation (AF) is more common in older adults and those with diabetes, and sodium-glucose cotransporter-2 inhibitors (SGLT2i) like dapagliflozin may help treat heart failure and reduce AF risk.
- This study explores how dapagliflozin impacts AF in a diabetic rat model and looks into the role of the enzyme Sirtuin 1 (SIRT1).
- Findings indicate that dapagliflozin lessens cardiac fibrosis and AF by influencing SIRT1, improving cell functions under high glucose conditions, and reducing harmful effects when SIRT1 is inhibited.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!